Close Menu

Europe

In Europe, Blueprint will commercialize the drug first in Germany as a treatment for advanced GIST patients with a PDGFRA D842V mutation.

The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.

Data presented at ESMO showed that in 175 adults and children with more than 20 kinds of tumors the drug on average can stave off progression for more than three years.

In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.

Interim results from a study in the Netherlands suggest whole-genome sequencing can be done fast enough to uncover treatment targets in metastatic cancer patients.

Data from ESMO positioned the competing checkpoint inhibitors as potential new standards of care in the first-line setting, but biomarker questions remain.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

A secondary analysis suggested that using NGS to identify patients with PTEN loss may be better than IHC in identifying best responders to treatment.

The decision is based on data from the PAOLA-1 trial, which focused on patients with tumors that have homologous repair recombination deficiency.

Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.

Pages